{
    "clinical_study": {
        "@rank": "137827", 
        "acronym": "sustenna", 
        "arm_group": {
            "arm_group_label": "paliperidone palmitate", 
            "arm_group_type": "Experimental", 
            "description": "paliperidone palmitate"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is the evaluation of effectiveness of paliperidone palmitate\n      within three different group of schizophrenia patients."
        }, 
        "brief_title": "The Effect of Paliperidone Palmitate in Schizophrenia", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Schizophrenia", 
        "condition_browse": {
            "mesh_term": "Schizophrenia"
        }, 
        "detailed_description": {
            "textblock": "In this study, the investigators are going to examine the effectiveness of paliperidone\n      palmitate after changing from other antipsychotics. This study design is a Prospective\n      Naturalistic Case Series Study. The effectiveness of paliperidone would be compared within\n      three different groups of schizophrenia. Investigators would also assess the safety during\n      24 weeks follow up period."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age: 18 ~ 65\n\n          -  Patient with schizophrenia according to DSM-IV criteria\n\n          -  Patient have signed on the informed consent, and well understood the objective and\n             procedure of this study.\n\n          -  PANSSS total score <120\n\n          -  each Score of disorganized thought, paranoia hallucinatory behavior, abnormal tbought\n             contests < 16\n\n          -  three different groups ( other antipsychotics refractory schizophrenia patitents :\n             CGI> 4 chronic akathisia : DIEPSS overall severity >1, at least 1 month lasting\n             symptoms poor compliance schizophrenia : CRS <3)\n\n          -  Competent patient who is manage to answer the questionnaires.\n\n          -  In case of female at child-bearing age, consent to use appropriate contraceptive\n             methods(oral pill, contraceptive injection, intrauterine device, double barrier\n             method and contraceptive patch) during entire duration of this study.\n\n        Exclusion Criteria:\n\n          -  No history of antipsychotics prescription\n\n          -  History of NMS(Neuroleptic malignant syndrome)\n\n          -  Allergic reaction or hypersensitive reaction of risperidone or paliperidone ER\n\n          -  clozapine medication within 1 month before screening\n\n          -  SSRI, MAOI, TCA medication within 2 months\n\n          -  Lithium, valproic acid, carbamazepine, topiramate, lamotrigine medication starting\n             within 2 months\n\n          -  patient who is supposed to be impossible to participate to this study due to clinical\n             risk of suicide or aggressive behavior based on clinician's opinion\n\n          -  current or previous history of drug depedence according to DSM-IV\n\n          -  Pregnant or breast-feeding female patient\n\n          -  Significant biochemical or hematological abnormality or abnormal finding of\n             urinalysis, based on clinician's opinion\n\n          -  history of cardiac disease, which is related to QT prolongation(sick sinus, complete\n             AV block, CHF, ventricular tachycardia, hypokalemia or hypocalcemia)\n\n          -  History of participating to other investigational drug trial within 1month prior to\n             screening\n\n          -  Investigator or employee at clinical trial center, personnel related to investigator\n             or trial center on this or other study, or family of employee or investigator"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01860781", 
            "org_study_id": "R092670-SCH-4008"
        }, 
        "intervention": {
            "arm_group_label": "paliperidone palmitate", 
            "description": "paliperidone palmitate 150mgeq(1 day), 100mgeq(8days), 75mg(monthly)", 
            "intervention_name": "paliperidone palmitate", 
            "intervention_type": "Drug", 
            "other_name": "paliperidone palmitate(sustenna)"
        }, 
        "intervention_browse": {
            "mesh_term": "9-hydroxy-risperidone"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Schizophrenia", 
            "Injection", 
            "Switch", 
            "Paliperidone", 
            "refractory, chronic akathisia, poor complianc"
        ], 
        "lastchanged_date": "December 5, 2013", 
        "location": {
            "contact": {
                "email": "b.kim0626@gmail.com", 
                "last_name": "Bora Kim, MD", 
                "phone": "82 2 2072 2457"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Seoul National University Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "official_title": "The Effect of Paliperidone Palmitate in Schizophrenia: A Prospective Naturalistic Case Series Study", 
        "overall_contact": {
            "email": "b.kim0626@gmail.com", 
            "last_name": "Bora Kim, MD", 
            "phone": "82 2 2072 2457"
        }, 
        "overall_official": {
            "affiliation": "Seoul National University Hospital", 
            "last_name": "Yong Min Ahn, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "CGI-S,I: Clinical Global Impression-Severity, Improvement", 
            "safety_issue": "No", 
            "time_frame": "24 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01860781"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Seoul National University Hospital", 
            "investigator_full_name": "Yong Min Ahn", 
            "investigator_title": "professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "PANSS: Positive and Negative Syndrome Scale", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "CRS: Clinician Rating Scale", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "KDAI-10: Korean Drug Attitude Inventory-10", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "SWN: Subjective Well-being Under Neuroleptic Treatment", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "DIEPSS: Drug-Induced ExtraPyramidal Symptoms Sclae", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "injection site pain -VAS: Visual Analog Scale", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "LUNSERS: Liverpool University Neuroleptic Side Effect Rating Scale", 
                "safety_issue": "Yes", 
                "time_frame": "24 weeks"
            }
        ], 
        "source": "Seoul National University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Seoul National University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2011", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}